TM4SF1 regulates apoptosis, cell cycle and ROS metabolism via the PPARγ-SIRT1 feedback loop in human bladder cancer cells

Cao, Rui; Wang, Gang; Qian, Kaiyu; Chen, Liang; Ju, Lingao; Qian, Guofeng; Wu, Chin‐Lee; Han, Dong; Jiang, Wei; Wu, Min; Xiao, Yu; Wang, Xinghuan

doi:10.1016/j.canlet.2017.11.015

Cited by 73 publications

(75 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar result was also obtained in the study that showed contribution of TM4SF1 loss to the invasion and migration of pancreatic cancer cells . However, other study showed that high expression of TM4SF1 is correlated with T stage, TNM stage, lymph node metastasis status of MIBC (muscle invasive bladder cancer) patients . It seems that the role of TM4SF1 in cancer progression and invasion is also tissue‐specific.…”

Section: Discussionsupporting

confidence: 84%

“…We also evaluated the prognostic significance of TM4SF1 in patients with GC and found that lower expression of TM4SF1 was associated with poorer overall survival as revealed by Kaplan–Meier analysis, suggesting that TM4SF1 could be a novel prognostic marker for patients with GC. This is different from cancers such as muscle‐invasive bladder cancer , pancreatic Cancer , and glioma where overexpression of TM4SF1 is linked to poor prognosis of these cancers. Therefore, the role of TM4SF1 expression as a prognostic marker is dependent on the types of cancers.…”

Section: Discussionmentioning

confidence: 82%

See 1 more Smart Citation

Clinical significance of TM4SF1 as a tumor suppressor gene in gastric cancer

et al. 2018

View full text Add to dashboard Cite

Transmembrane‐4‐L‐six‐family member‐1 (TM4SF1), a tumor‐associated antigen, is overexpressed in most epithelial cell carcinomas and a potential target for antibody‐mediated therapy. However, the role of TM4SF1 in gastric cancer has not been elucidated. The aim of this study was to investigate the clinical significance of TM4SF1 expression in gastric carcinoma (GC) tissues using 152 GC tissue samples and matched adjacent nontumor tissue samples analyzed by immunohistochemistry, and 13 fresh GC tissue samples analyzed by Western blotting. The results showed that TM4SF1 was heterogeneously expressed in normal gastric mucosa, with a high expression rate in fundus mucosa. Higher levels and strong expression rate of TM4SF1 were associated with GC tissues of higher‐grade differentiation. TM4SF1 levels were lower in gastric cancer tissues than gastric noncancerous tissues. Expression of TM4SF1 was not correlated with USP10 (P = 0.157), S100A12 (P = 0.479), p53 (P = 0.249), or Ki67 (P = 0.166) in GC. The expression of TM4SF1 was significantly and negatively correlated with depth of invasion (P = 0.031), nodal metastasis (P = 0.042), TNM stage (P = 0.030), and Lauren classification (P = 0.026). There was no significant correlation between TM4SF1 expression and age, gender, tumor size, or distant metastasis (P > 0.05). The expression of TM4SF1 was associated with well overall survival (P = 0.0164). The 5‐year survival rate for patients with GC showing TM4SF1 positive was 58.82% (10/17), and the median survival time was 78 months, higher than that (12.90%, 12/93) of patients who were TM4SF1 negative, whose median survival time was 62 months. These data suggested that low expression of TM4SF1 is associated with carcinogenesis and development, tumor progression and invasion of gastric cancer, and poor overall survival of patients with GC. TM4SF1 is a tumor suppressor for GC and a novel prognostic marker for patients with GC.

show abstract

Section: Discussionsupporting

confidence: 84%

Section: Discussionmentioning

confidence: 82%

Clinical significance of TM4SF1 as a tumor suppressor gene in gastric cancer

et al. 2018

View full text Add to dashboard Cite

show abstract

“…27,28 Until now, a plethora of single molecular biomarkers have been reported, [7][8][9] but only a few have been validated for clinical use or recommended by guidelines. [29][30][31] On the other hand, the predictive effect of a multiple gene signature has been highlighted. 32,33 In this study, we conducted GSVA to screen the most important Recent studies have revealed the involvement of EMT in the pathogenesis of cancers, including BLCA.…”

Section: Discussionmentioning

confidence: 99%

An EMT‐related gene signature for the prognosis of human bladder cancer

Cao

Yuan

et al. 2019

J Cellular Molecular Medi

Self Cite

154

120

View full text Add to dashboard Cite

The transition from non–muscle‐invasive bladder cancer (NMIBC) to muscle‐invasive bladder cancer (MIBC) is detrimental to bladder cancer (BLCA) patients. Here, we aimed to study the underlying mechanism of the subtype transition. Gene set variation analysis (GSVA) revealed the epithelial‐mesenchymal transition (EMT) signalling pathway with the most positive correlation in this transition. Then, we built a LASSO Cox regression model of an EMT‐related gene signature in BLCA. The patients with high risk scores had significantly worse overall survival (OS) and disease‐free survival (DFS) than those with low risk scores. The EMT‐related gene signature also performed favourably in the accuracy of prognosis and in the subtype survival analysis. Univariate and multivariate Cox regression analyses demonstrated that the EMT‐related gene signature, pathological N stage and age were independent prognostic factors for predicting survival in BLCA patients. Furthermore, the predictive nomogram model was able to effectively predict the outcome of BLCA patients by appropriately stratifying the risk score. In conclusion, we developed a novel EMT‐related gene signature that has tumour‐promoting effects, acts as a negative independent prognostic factor and might facilitate personalized counselling and treatment in BLCA.

show abstract

“…Our group has revealed a variety of potential biomarkers 32,38,39 based on transcriptome data of normal bladder tissues vs BCa which has been demonstrated to play a crucial role in cancer cell invasion and migration. 52 The association of vimentin and cytokeratin was also revealed in the transitional cell carcinoma genesis of urinary bladder patients, and thus could be a favourable marker in the early diagnosis of transitional BCa.…”

Section: Discussionmentioning

confidence: 99%

PPARγ inhibition regulates the cell cycle, proliferation and motility of bladder cancer cells

Cheng

Qian

Wang

et al. 2019

J Cellular Molecular Medi

Self Cite

View full text Add to dashboard Cite

Peroxisome proliferator‐activated receptor gamma (PPARγ) is a member of the nuclear receptor family of ligand‐activated transcription factors and plays an important role in regulating cell proliferation, inflammation and lipid and glucose homeostasis. Our results revealed that PPARγ was up‐regulated in human bladder cancer (BCa) tissues both at transcriptional and translational levels. Moreover, down‐regulation of PPARγ mRNA or inhibition of PPARγ function (using GW9662, antagonist of PPARγ) could significantly suppress the proliferation of BCa cells. Furthermore, the cell cycle arrested in G0/G1 phase was also induced by the down‐regulated PPARγ possibly through AKT‐mediated up‐regulation of p21/p27, whereas no significant transformation of apoptosis was observed. In addition, knockdown or inhibition of PPARγ might reduce the invasion and migration of BCa cells by affecting epithelial‐mesenchymal transition‐related proteins through AKT/GSK3β signalling pathway. Additionally, in vivo studies showed that BCa cell proliferation was significantly suppressed by GW9662. In conclusion, our results indicated that PPARγ might be crucial for BCa tumorigenesis by interfering with the motility and viability of BCa cells.

show abstract

TM4SF1 regulates apoptosis, cell cycle and ROS metabolism via the PPARγ-SIRT1 feedback loop in human bladder cancer cells

Cited by 73 publications

References 65 publications

Clinical significance of TM4SF1 as a tumor suppressor gene in gastric cancer

Clinical significance of TM4SF1 as a tumor suppressor gene in gastric cancer

An EMT‐related gene signature for the prognosis of human bladder cancer

PPARγ inhibition regulates the cell cycle, proliferation and motility of bladder cancer cells

Contact Info

Product

Resources

About